Drugs / ARX517
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07082920 | Jul 2025 → Jan 2027 expected | prostate neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT04662580 | May 2021 → Dec 2026 expected | metastatic prostate carcinoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARX517 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04662580 ↗ |
| Known as | JNJ-95298177 | “ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer” NCT04662580 ↗ |
| Modality | Monoclonal antibody | “humanized anti-PSMA monoclonal antibody (mAb)” NCT04662580 ↗ |
| Route | Intravenous | “ARX517 will be administered via intravenous (IV) infusion” NCT04662580 ↗ |